O6-methylguanyl DNA methyltransferase (MGMT), a DNA repair enzyme that counteracts the toxicity of TMZ, plays an important role in the proliferation and therapeutic resistance of GBM and remains the most significant biomarker in clinical decision making, especially in GBM recurrence (8, 9). This evidence concerns the gene LIG4 and glioblastoma.